| Sonstiges: |
- Nachgewiesen in: MEDLINE
- Sprachen: English
- Publication Type: Journal Article
- Language: English
- [Birth Defects Res] 2024 Apr; Vol. 116 (4), pp. e2336.
- MeSH Terms: Agmatine* / pharmacology ; Autism Spectrum Disorder* / chemically induced ; Autism Spectrum Disorder* / drug therapy ; Autism Spectrum Disorder* / prevention & control ; Animals ; Female ; Male ; Mice ; Pregnancy ; Brain-Derived Neurotrophic Factor ; Calcium Carbonate ; Rodentia ; Signal Transduction ; Social Behavior ; Valproic Acid / adverse effects
- References: Ahmad, S. F., Ansari, M. A., Nadeem, A., Alzahrani, M. Z., Bakheet, S. A., & Attia, S. M. (2018). Resveratrol improves neuroimmune dysregulation through the inhibition of neuronal toll‐like receptors and COX‐2 signaling in BTBR T(+) Itpr3(tf)/J mice. Neuromolecular Medicine, 20, 133–146. ; Ahmad, S. F., Ansari, M. A., Nadeem, A., Bakheet, S. A., Al‐Ayadhi, L. Y., & Attia, S. M. (2017). Toll‐like receptors, NF‐kappaB, and IL‐27 mediate adenosine A2A receptor signaling in BTBR T(+) Itpr3(tf)/J mice. Progress in Neuro‐Psychopharmacology & Biological Psychiatry, 79, 184–191. ; Ahmad, S. F., Ansari, M. A., Nadeem, A., Bakheet, S. A., Almutairi, M. M., & Attia, S. M. (2017). Adenosine A2A receptor signaling affects IL‐21/IL‐22 cytokines and GATA3/T‐bet transcription factor expression in CD4(+) T cells from a BTBR T(+) Itpr3tf/J mouse model of autism. Journal of Neuroimmunology, 311, 59–67. ; Ahmad, S. F., Ansari, M. A., Nadeem, A., Bakheet, S. A., Alqahtani, F., Alhoshani, A. R., Alasmari, F., Alsaleh, N. B., & Attia, S. M. (2020). 5‐Aminoisoquinolinone attenuates social behavior deficits and immune abnormalities in the BTBR T(+) Itpr3(tf)/J mouse model for autism. Pharmacology, Biochemistry, and Behavior, 189, 172859. ; Ansari, M. A., Attia, S. M., Nadeem, A., Bakheet, S. A., Raish, M., Khan, T. H., Al‐Shabanah, O. A., & Ahmad, S. F. (2017). Activation of adenosine A2A receptor signaling regulates the expression of cytokines associated with immunologic dysfunction in BTBR T(+) Itpr3(tf)/J mice. Molecular and Cellular Neurosciences, 82, 76–87. ; Arai, T., Kamagata, K., Uchida, W., Andica, C., Takabayashi, K., Saito, Y., Tuerxun, R., Mahemuti, Z., Morita, Y., Irie, R., Kirino, E., & Aoki, S. (2023). Reduced neurite density index in the prefrontal cortex of adults with autism assessed using neurite orientation dispersion and density imaging. Frontiers in Neurology, 14, 1110883. ; Cetin, I., Tezdig, I., Tarakcioglu, M. C., Kadak, M. T., Demirel, O. F., & Ozer, O. F. (2016). Serum levels of glial fibrillary acidic protein and Nogo‐A in children with autism spectrum disorders. Biomarkers, 21, 614–618. ; Chaliha, D., Albrecht, M., Vaccarezza, M., Takechi, R., Lam, V., Al‐Salami, H., & Mamo, J. (2020). A systematic review of the valproic‐acid‐induced rodent model of autism. Developmental Neuroscience, 42, 12–48. ; Chisholm, K., Lin, A., Abu‐Akel, A., & Wood, S. J. (2015). The association between autism and schizophrenia spectrum disorders: A review of eight alternate models of co‐occurrence. Neuroscience and Biobehavioral Reviews, 55, 173–183. ; Chou, L. Y., Chao, Y. M., Peng, Y. C., Lin, H. C., & Wu, Y. L. (2020). Glucosamine enhancement of BDNF expression and animal cognitive function. Molecules, 25, 3667. ; Christensen, J., Gronborg, T. K., Sorensen, M. J., Schendel, D., Parner, E. T., Pedersen, L. H., & Vestergaard, M. (2013). Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA, 309, 1696–1703. ; Clements, B. M., Peterson, C. D., Kitto, K. F., Caye, L. D., Wilcox, G. L., & Fairbanks, C. A. (2023). Biodistribution of agmatine to brain and spinal cord after systemic delivery. The Journal of Pharmacology and Experimental Therapeutics, 387, 328–336. ; Dixit, M. P., Sammeta, S. S., Dhokne, M. D., Mangrulkar, S., Upadhya, M. A., Umekar, M. J., Taksande, B. G., & Kotagale, N. R. (2022). Chronic agmatine treatment prevents olanzapine‐induced obesity and metabolic dysregulation in female rats. Brain Research Bulletin, 191, 69–77. ; Esnafoglu, E., & Irende, I. (2018). Decreased plasma agmatine levels in autistic subjects. Journal of Neural Transmission (Vienna), 125, 735–740. ; Freitas, A. E., Neis, V. B., & Rodrigues, A. L. S. (2016). Agmatine, a potential novel therapeutic strategy for depression. European Neuropsychopharmacology, 26, 1885–1899. ; Gorbatyuk, O. S., Milner, T. A., Wang, G., Regunathan, S., & Reis, D. J. (2001). Localization of agmatine in vasopressin and oxytocin neurons of the rat hypothalamic paraventricular and supraoptic nuclei. Experimental Neurology, 171, 235–245. ; Guimaraes‐Souza, E. M., Joselevitch, C., Britto, L. R. G., & Chiavegatto, S. (2019). Retinal alterations in a pre‐clinical model of an autism spectrum disorder. Molecular Autism, 10, 19. ; Hassanshahi, A., Janahmadi, M., Razavinasab, M., Ilaghi, M., Kohlmeier, K. A., Hassanshahi, E., & Shabani, M. (2023). Administration of agmatine prior to physical or psychological stress in pregnant mice ameliorates behavioural and cognitive deficits in female offspring. International Journal of Developmental Neuroscience, 83, 442–455. ; Himanshu, Dharmila, Sarkar, D., & Nutan. (2020). A review of behavioral tests to evaluate different types of anxiety and anti‐anxiety effects. Clinical Psychopharmacology and Neuroscience, 18, 341–351. ; Ishikawa, T., Obara, T., Jin, K., Nishigori, H., Miyakoda, K., Suzuka, M., Ikeda‐Sakai, Y., Akazawa, M., Nakasato, N., Yaegashi, N., Kuriyama, S., & Mano, N. (2019). Examination of the prescription of antiepileptic drugs to prenatal and postpartum women in Japan from a health administrative database. Pharmacoepidemiology and Drug Safety, 28, 804–811. ; Jeon, S. J., Kwon, H., Bae, H. J., Gonzales, E. L., Kim, J., Chung, H. J., Kim, D. H., Ryu, J. H., & Shin, C. Y. (2022). Agmatine relieves behavioral impairments in fragile X mice model. Neuropharmacology, 219, 109234. ; Kim, J. W., Seung, H., Kim, K. C., Gonzales, E. L. T., Oh, H. A., Yang, S. M., Ko, M. J., Han, S. H., Banerjee, S., & Shin, C. Y. (2017). Agmatine rescues autistic behaviors in the valproic acid‐induced animal model of autism. Neuropharmacology, 113, 71–81. ; Kim, K. C., Kim, P., Go, H. S., Choi, C. S., Yang, S. I., Cheong, J. H., Shin, C. Y., & Ko, K. H. (2011). The critical period of valproate exposure to induce autistic symptoms in Sprague‐Dawley rats. Toxicology Letters, 201, 137–142. ; Kim, K. C., Lee, D. K., Go, H. S., Kim, P., Choi, C. S., Kim, J. W., Jeon, S. J., Song, M. R., & Shin, C. Y. (2014). Pax6‐dependent cortical glutamatergic neuronal differentiation regulates autism‐like behavior in prenatally valproic acid‐exposed rat offspring. Molecular Neurobiology, 49, 512–528. ; Kinney, D. K., Munir, K. M., Crowley, D. J., & Miller, A. M. (2008). Prenatal stress and risk for autism. Neuroscience and Biobehavioral Reviews, 32, 1519–1532. ; Kotagale, N. R., Chopde, C. T., Umekar, M. J., & Taksande, B. G. (2015). Chronic agmatine treatment prevents behavioral manifestations of nicotine withdrawal in mice. European Journal of Pharmacology, 754, 190–198. ; Kotagale, N. R., Taksande, B. G., & Inamdar, N. N. (2019). Neuroprotective offerings by agmatine. Neurotoxicology, 73, 228–245. ; Kuo, J. R., Lo, C. J., Chio, C. C., Chang, C. P., & Lin, M. T. (2007). Resuscitation from experimental traumatic brain injury by agmatine therapy. Resuscitation, 75, 506–514. ; Leo, A., De Caro, C., Mainardi, P., Tallarico, M., Nesci, V., Marascio, N., Striano, P., Russo, E., Constanti, A., De Sarro, G., & Citraro, R. (2021). Increased efficacy of combining prebiotic and postbiotic in mouse models relevant to autism and depression. Neuropharmacology, 198, 108782. ; Levy, S. E., Mandell, D. S., & Schultz, R. T. (2009). Autism. Lancet, 374, 1627–1638. ; Li, L., Li, M., Lu, J., Ge, X., Xie, W., Wang, Z., Li, X., Li, C., Wang, X., Han, Y., Wang, Y., Zhong, L., Xiang, W., Huang, X., Chen, H., & Yao, P. (2018). Prenatal progestin exposure is associated with autism spectrum disorders. Frontiers in Psychiatry, 9, 611. ; Li, X., Lin, J., Hua, Y., Gong, J., Ding, S., Du, Y., Wang, X., Zheng, R., & Xu, H. (2021). Agmatine alleviates epileptic seizures and hippocampal neuronal damage by inhibiting gasdermin D‐mediated pyroptosis. Frontiers in Pharmacology, 12, 627557. ; Malkova, N. V., Yu, C. Z., Hsiao, E. Y., Moore, M. J., & Patterson, P. H. (2012). Maternal immune activation yields offspring displaying mouse versions of the three core symptoms of autism. Brain, Behavior, and Immunity, 26, 607–616. ; Mishra, M. K., Kukal, S., Paul, P. R., Bora, S., Singh, A., Kukreti, S., Saso, L., Muthusamy, K., Hasija, Y., & Kukreti, R. (2021). Insights into structural modifications of valproic acid and their pharmacological profile. Molecules, 27, 104. ; Moy, S. S., Nadler, J. J., Perez, A., Barbaro, R. P., Johns, J. M., Magnuson, T. R., Piven, J., & Crawley, J. N. (2004). Sociability and preference for social novelty in five inbred strains: An approach to assess autistic‐like behavior in mice. Genes, Brain, and Behavior, 3, 287–302. ; Nadeem, A., Ahmad, S. F., Al‐Harbi, N. O., Attia, S. M., Bakheet, S. A., Alsanea, S., Ali, N., Albekairi, T. H., & Alsaleh, N. B. (2021). Aggravation of autism‐like behavior in BTBR T+tf/J mice by environmental pollutant, di‐(2‐ethylhexyl) phthalate: Role of nuclear factor erythroid 2‐related factor 2 and oxidative enzymes in innate immune cells and cerebellum. International Immunopharmacology, 91, 107323. ; Nadeem, A., Ahmad, S. F., El‐Sherbeeny, A. M., Al‐Harbi, N. O., Bakheet, S. A., & Attia, S. M. (2018). Systemic inflammation in asocial BTBR T(+) tf/J mice predisposes them to increased psoriatic inflammation. Progress in Neuro‐Psychopharmacology & Biological Psychiatry, 83, 8–17. ; Nicolini, C., & Fahnestock, M. (2018). The valproic acid‐induced rodent model of autism. Experimental Neurology, 299, 217–227. ; Ornoy, A. (2009). Valproic acid in pregnancy: How much are we endangering the embryo and fetus? Reproductive Toxicology, 28, 1–10. ; Pu, Y., Ma, L., Shan, J., Wan, X., Hammock, B. D., & Hashimoto, K. (2021). Autism‐like behaviors in male juvenile offspring after maternal glyphosate exposure. Clinical Psychopharmacology and Neuroscience, 19, 554–558. ; Ranger, P., & Ellenbroek, B. A. (2016). Perinatal influences of valproate on brain and behaviour: An animal model for autism. Current Topics in Behavioral Neurosciences, 29, 363–386. ; Romoli, M., Mazzocchetti, P., D'Alonzo, R., Siliquini, S., Rinaldi, V. E., Verrotti, A., Calabresi, P., & Costa, C. (2019). Valproic acid and epilepsy: From molecular mechanisms to clinical evidences. Current Neuropharmacology, 17, 926–946. ; Sharawy, M. H., Abdelrahman, R. S., & El‐Kashef, D. H. (2018). Agmatine attenuates rhabdomyolysis‐induced acute kidney injury in rats in a dose dependent manner. Life Sciences, 208, 79–86. ; Shopsin, B. (2013). The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: A pilot study. Acta Neuropsychiatrica, 25, 113–118. ; Taksande, B. G., Chopde, C. T., Umekar, M. J., & Kotagale, N. R. (2015). Agmatine attenuates lipopolysaccharide induced anorexia and sickness behavior in rats. Pharmacology, Biochemistry, and Behavior, 132, 108–114. ; Tatem, K. S., Quinn, J. L., Phadke, A., Yu, Q., Gordish‐Dressman, H., & Nagaraju, K. (2014). Behavioral and locomotor measurements using an open field activity monitoring system for skeletal muscle diseases. Journal of Visualized Experiments, (91), 51785. ; Uzbay, T. I. (2012). The pharmacological importance of agmatine in the brain. Neuroscience and Biobehavioral Reviews, 36, 502–519. ; Vajda, F. J. E., O'Brien, T. J., Graham, J. E., Hitchcock, A. A., Lander, C. M., & Eadie, M. J. (2019). Valproate‐associated foetal malformations—Rates of occurrence, risks in attempted avoidance. Acta Neurologica Scandinavica, 139, 42–48. ; Vinchurney, M. D., Dhokne, M. D., Kotagale, N., Umekar, M. J., & Taksande, B. (2023). Agmatine prevents the manifestation of impulsive burying and depression‐like behaviour in progesterone withdrawn female rats. Hormones and Behavior, 152, 105361. ; Wang, Y., Zhao, S., Liu, X., Zheng, Y., Li, L., & Meng, S. (2018). Oxytocin improves animal behaviors and ameliorates oxidative stress and inflammation in autistic mice. Biomedicine & Pharmacotherapy, 107, 262–269. ; Wu, D., Wu, F., Lin, R., Meng, Y., Wei, W., Sun, Q., & Jia, L. (2020). Impairment of learning and memory induced by perinatal exposure to BPA is associated with ERalpha‐mediated alterations of synaptic plasticity and PKC/ERK/CREB signaling pathway in offspring rats. Brain Research Bulletin, 161, 43–54. ; Xu, W., Gao, L., Li, T., Shao, A., & Zhang, J. (2018). Neuroprotective role of agmatine in neurological diseases. Current Neuropharmacology, 16, 1296–1305. ; Zahedi, E., Sadr, S. S., Sanaeierad, A., & Roghani, M. (2023). Valproate‐induced murine autism spectrum disorder is associated with dysfunction of amygdala parvalbumin interneurons and downregulation of AMPK/SIRT1/PGC1alpha signaling. Metabolic Brain Disease, 38, 2093–2103. ; Zohny, S. M., Habib, M. Z., Mohamad, M. I., Elayat, W. M., Elhossiny, R. M., El‐Salam, M. F. A., Hassan, G. A. M., & Aboul‐Fotouh, S. (2023). Memantine/aripiprazole combination alleviates cognitive dysfunction in valproic acid rat model of autism: Hippocampal CREB/BDNF signaling and glutamate homeostasis. Neurotherapeutics, 20, 464–483.
- Grant Information: Y20190096 Science and Technology Plan Project of Wenzhou Municipality; 2020KY180 Medical Health Science and Technology Project of Zhejiang Provincial Health Commission
- Contributed Indexing: Keywords: BDNF; CREB; ERK; agmatine; autism spectrum disorder; valproate
- Substance Nomenclature: 70J407ZL5Q (Agmatine) ; 0 (Brain-Derived Neurotrophic Factor) ; H0G9379FGK (Calcium Carbonate) ; 614OI1Z5WI (Valproic Acid)
- Entry Date(s): Date Created: 20240416 Date Completed: 20240417 Latest Revision: 20240422
- Update Code: 20240423
|
